Skip to content

We should be wary of campaigns by pharmaceutical companies to destigmatise obesity( BMJ, 11 November 2026)

Summary

This BMJ article argues that while pharmaceutical company campaigns to destigmatise obesity may promote accurate and important messages about compassion and the biological complexity of obesity, they also deserve critical scrutiny because the companies behind them have a commercial interest in expanding the market for obesity treatments.

Using Eli Lilly’s UK “Obesity is a Disease” campaign as an example, the authors contend that such campaigns can subtly encourage people to seek clinical solutions, particularly weight-loss drugs such as tirzepatide, while drawing attention away from the broader social, environmental and economic causes of obesity, including deprivation, food environments and urban planning.

We should be wary of campaigns by pharmaceutical companies to destigmatise obesity( BMJ, 11 November… https://www.bmj.com/content/395/bmj-2026-101360

User Feedback

Recommended Comments

There are no comments to display.

Create an account or sign in to comment

Registered address: Patient Safety Learning, China Works SB203, 100 Black Prince Road Vauxhall, London, SE1 7SJ

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.